Bath & Body Works Inc vs 22nd Century Group Inc — how do they compare? Bath & Body Works Inc trades at $19.4 (market cap $4.04B), while 22nd Century Group Inc trades at $4.19 (market cap $1.45M). The key difference: Bath & Body Works Inc is far larger — about 2786.2× 22nd Century Group Inc's market cap, and Bath & Body Works Inc pays a 3.99% dividend while 22nd Century Group Inc pays none. Which is the better fit depends on your goals.
| BBWI | XXII | |
|---|---|---|
Market Cap | $4.04B | $1.45M |
Sector | Consumer Cyclical | Technology |
52-Week High | $33.11 | $1.47K |
52-Week Low | $14.85 | $3.90 |
Enterprise Value | $7.93B | -$6.78M |
Dividend Yield | 3.99% | — |
Signals from Pluang's Aura AI — not financial advice
BBWI trades at $20.42, up 0.44% today, with a bearish technical signal but attractive valuation metrics including a P/E of 5.8 and P/S of 0.58. Recent earnings show mixed quarterly beats, with Q1 2026 exceeding expectations. The company maintains solid profitability with a 10.03% net income margin and positive cash flow trends projected for 2026. Strategic initiatives include a new Ulta Beauty partnership and international expansion to drive growth amid declining revenue trends.
Outlook: BBWI presents a value opportunity with deep valuation discounts and operational strengths, though persistent revenue declines and high debt pose risks. Analyst consensus is cautiously optimistic with a $22 price target, suggesting modest upside potential if turnaround efforts gain traction against competitive and macroeconomic headwinds.
XXII trades at $4.10, down 3.07% today, with a bearish technical signal from moving averages. The company shows severe financial distress with a negative gross profit margin of -52.19% and net income margin of -65.76% for 2025. Recent news highlights expansion of VLN reduced-nicotine cigarettes in California and New York, aiming to capture market share. A 20:1 reverse stock split occurred on June 12, 2026, to adjust share structure.
The outlook remains high-risk due to persistent losses and cash burn, though analyst consensus is 75% buy-rated. Investment opportunity hinges on successful commercialization of VLN products and FDA regulatory renewals. Key risks include execution challenges, intense competition, and reliance on financing to sustain operations amid negative cash flow from operations.
Trailing returns across standard periods
Bath & Body Works is a specialty home fragrance and fragrant body care retailer operating under the Bath & Body Works, C.O. Bigelow, and White Barn brands. The company generates most of its business in North America, with less than 5% of sales from international markets in fiscal 2021. For fiscal 2021, 72% of sales stemmed from the brick-and-mortar network (which is composed of more than 1,700 retail stores), up from 65% in 2020, as consumer shopping patterns began to return to normal. Future growth is expected from store reformatting, digital and international channels, as well as new category expansion.
Read more on BBWI →22nd Century Group is a plant biotechnology company that uses genetic engineering and gene editing to control the levels of nicotine in tobacco plants. Its flagship product line, VLN®, is the first and only combustible cigarette authorized by the FDA as a Modified Risk Tobacco Product (MRTP), containing 95% less nicotine than traditional cigarettes to help adult smokers smoke less.
Read more on XXII →